Disease detection and management might benefit from external imaging of disease gene mRNAs. Previously we designed molecular imaging nanoparticles (MINs) based on peptide nucleic acids complementary to cancer gene mRNAs. The MINs included contrast agents and analogs of insulin-like growth factor 1 (IGF-1). Analysis of MIN tumor uptake data showed stronger binding in tumors than in surrounding tissues. We hypothesized that MINs with an IGF-1 analog stay in circulation by binding to IGF-binding proteins. To test that hypothesis, we fit the tissue distribution results of several MINs in xenograft-bearing mice to a physiological pharmacokinetics model. Fitting experimental tissue distribution data to model-predicted mass transfer of MINs from blood into organs and tumors converged only when the parameter for MINs bound to circulating IGF-binding proteins was set to 10%–20% of the injected MIN dose. This result suggests that previous mouse imaging trials used more MINs than necessary. This prediction can be tested by a ramp of decreasing doses.
BARBEER.W., PERRYB.D., RER.N., MURGOJ.P.1992. Microsphere and dilution techniques for the determination of blood flows and volumes in conscious mice. Am. J. Physiol., 263:R728–R733.
3.
BARNETTS.A., WIDDOWSONE.M.1965. Organ-weights and body-composition in mice bred for many generations at −3 degrees Celsius. Proc. R. Soc. Lond. B. Biol. Sci., 162:502–516.
BASTIANS.E.P., WALTONP.E., BALLARDF.J., BELFORDD.A.1999. Transport of IGF-I across epithelial cell monolayers. J. Endocrinol., 162:361–369.
6.
BASTIANS.E.P., WALTONP.E., BELFORDD.A.1997. Paracellular transport of insulin-like growth factor-I (IGF-I) across human umbilical vein endothelial cell monolayers. J. Cell. Physiol., 170:290–298.
7.
BAXTERL.T., ZHUH., MACKENSEND.G., JAINR.K.1994. Physiologically-based pharmacokinetic model for specific and nonspecific monoclonal-antibodies and fragments in normal-tissues and human tumor xenografts in nude-mice. Cancer Res., 54:1517–1528.
8.
BAXTERR.C., MARTINJ.L.1986. Radioimmunoassay of growth-hormone dependent insulin-like growth-factor binding-protein in human-plasma. J. Clin. Invest., 78:1504–1512.
9.
BLAKEYG.E., NESTOROVI.A., ARUNDELP.A., AARONSL.J., ROWLANDM.1997. Quantitative structure-pharmacokinetics relationships: I. Development of a whole-body physiologically based model to characterize changes in pharmacokinetics across a homologous series of barbiturates in the rat. J. Pharmacokinet. Biopharm., 25:277–312.
10.
BOROUJERDIM.A., JONESR.H., SONKSENP.H., RUSSELL-JONESD.L.1997. Simulation of IGF-I pharmacokinetics after infusion of recombinant IGF-I in human subjects. Am. J. Physiol. Endocrinol. Metab., 36:E438–E447.
11.
BOROUJERDIM.A., SONKSENP.H., JONESR.H.1994. A compartmental model for simulation of IGF-I kinetics and metabolism. Methods Inf. Med., 33:514–521.
12.
CALDERW.A.1984. Size, function, and life history. Harvard University Press: Cambridge, Massachusetts, 13–25.
13.
CHAKRABARTIA., ZHANGK., ARUVAM.R., CARDIC.A., OPITZA.W., WAGNERN.J., THAKURM.L., WICKSTROME.2007. Radiohybridization PET imaging of KRAS G12D mRNA expression in human pancreas cancer xenografts with [Cu-64]DO3A-peptide nucleic acid-peptide nanoparticles. Cancer Biol. Ther., 6:948–956.
14.
CRISPENSC.G.1975a. Handbook on the laboratory mouse. Charles C. Thomas Publisher: Springfield, Illinois, 95–123.
15.
CRISPENSC.G.1975b. Handbook on the laboratory mouse. Charles C. Thomas Publisher: Springfield, Illinois, 63–92.
16.
DELAFONTAINEP., SONGY.H., LIY.X.2004. Expression, regulation, and function of IGF-1, IGF-1R, and IGF-1 binding proteins in blood vessels. Arterioscler. Thromb. Vasc. Biol., 24:435–444.
17.
EBLINGW.F., WADAD.R., STANSKID.R.1994. From piecewise to full physiological pharmacokinetic modeling—applied to thiopental disposition in the rat. J. Pharmacokinet. Biopharm., 22:259–292.
18.
EVERETTN.B., SIMMONSB., LASHERE.P.1956. Distribution of blood (Fe-59) and plasma (I-131) volumes of rats determined by liquid nitrogen freezing. Circ. Res., 4:419–424.
19.
FARIAA.C.S., VELDHUISJ.D., THORNERM.O., VANCEM.L.1989. Half-time of endogenous growth-hormone (GH) disappearance in normal man after stimulation of GH secretion by GH-releasing hormone and suppression with somatostatin. J. Clin. Endocrinol. Metab., 68:535–541.
20.
FORSTEN-WILLIAMSK., CASSINOT.R., DELOL.J., BELLISA.D., ROBINSONA.S., RYANT.E.2007. Enhanced insulin-like growth factor-I (IGF-I) cell association at reduced pH is dependent on IGF binding protein-3 (IGFBP-3) interaction. J. Cell. Physiol., 210:298–308.
21.
GEARHARTJ.M., JEPSONG.W., CLEWELLH.J., ANDERSENM.E., CONOLLYR.B.1990. Physiologically based pharmacokinetic and pharmacodynamic model for the inhibition of acetylcholinesterase by diisopropylfluorophosphate. Toxicol. Appl. Pharmacol., 106:295–310.
22.
GERLOWSKIL.E., JAINR.K.1983. Physiologically based pharmacokinetic modeling—principles and applications. J. Pharm. Sci., 72:1103–1127.
23.
GILLESPIEC.M., HAZELS.J., WALTONP.E., MARTINA.A.1996. Effects of chronic renal failure on plasma clearance of insulin-like growth factor I, des-(1-3)IGF-I, and LR3IGF-I. Am. J. Physiol. Endocrinol. Metab., 271:E649–E657.
24.
GJEDDES.B., GJEDDEA.1980. Organ blood-flow rates and cardiac-output of the BALB/c mouse. Comp. Biochem. Physiol. A. Physiol., 67:671–674.
25.
HILMASD.E., GILLETTEE.L.1974. Morphometric analyses of microvasculature of tumors during growth and after X-irradiation. Cancer, 33:103–110.
26.
JAINR.K.1988. Determinants of tumor blood-flow—a review. Cancer Res., 48:2641–2658.
27.
JEMALA., SIEGELR., WARDE., MURRAYT., XUJ.Q., THUNM.J.2007. Cancer statistics, 2007. CA. Cancer J. Clin., 57:43–66.
28.
JUULA.2003. Serum levels of insulin-like growth factor I and its binding proteins in health and disease. Growth Horm. IGF Res., 13:113–170.
29.
KALLINOWSKIF., SCHLENGERK.H., RUNKELS., KLOESM., STOHRERM., OKUNIEFFP., VAUPELP.1989. Blood-flow, metabolism, cellular microenvironment, and growth-rate of human-tumor xenografts. Cancer Res., 49:3759–3764.
30.
KOBERF., ILTISI., COZZONEP.J., BERNARDM.2004. Cine-MRI assessment of cardiac function in mice anesthetized with ketamine/xylazine and isoflurane. Magn. Reson. Mater. Phys. Biol. Med., 17:157–161.
31.
LINDSTEDTS.L., SCHAEFFERP.J.2002. Use of allometry in predicting anatomical and physiological parameters of mammals. Lab. Anim., 36:1–19.
32.
MARNINGASP.A., DEGUZZMANL.R., HOLLENBACHS.J., VOLKK.A., BELLAMYR.F.1986. Regional blood flow during hypothermic arrest. Ann. Emerg. Med., 15:390–396.
33.
MELGARS., KARLSSONA., MICHAELSSONE.M.2005. Acute colitis induced by dextran sulfate sodium progresses to chronicity in C57BL/6 but not in BALB/c mice: correlation between symptoms and inflammation. Am. J. Physiol. –Gastrointest. Liver Physiol., 288:G1328–G1338.
34.
MIZUNON., KATOY., IWAMOTOM., URAEA., AMAMOTOT., NIWAT., SUGIYAMAY.2001. Kinetic analysis of the disposition of insulin-like growth factor 1 in healthy volunteers. Pharm. Res., 18:1203–1209.
35.
OPITZA.W.2008. Structural and functional investigations of a molecular imaging nanoparticle for magnetic resonance imaging of oncogene expression in the pancreas, Ph.D., Chemical Engineering. University of Delaware: Newark, 457.
36.
PAYEJ.M.D., FORSTEN-WILLIAMSK.2006. Regulation of insulin-like growth factor-I (IGF-I) delivery by IGF binding proteins and receptors. Ann. Biomed. Eng., 34:618–632.
37.
PENGB., ANDREWSJ., NESTOROVI., BRENNANB., NICKLINP., ROWLANDM.2001. Tissue distribution and physiologically based pharmacokinetics of antisense phosphorothioate oligonucleotide ISIS 1082 in rat. Antisense Nucleic Acid Drug Dev., 11:15–27.
38.
PLATAE.J., MURPHYW.H.1972. Growth and hematologic properties of BALB/Wm strain of inbred mice. Lab. Anim. Sci., 22:712–720.
39.
QUICKD.J., SHULERM.L.1999. Use of in vitro data for construction of a physiologically based pharmacokinetic model for naphthalene in rats and mice to probe species differences. Biotechnol. Prog., 15:540–555.
40.
RACZKAE., QUINTANAA., POGGIA., DONATIM.B.1983. Distribution of cardiac-output during development of 2 metastasizing murine tumors. Eur. J. Cancer Clin. Oncol., 19:1021–1029.
41.
SARAV.R., HALLK.1990. Insulin-like growth-factors and their binding-proteins. Physiol. Rev., 70:591–614.
42.
SARINS.K., SABBAC., GROSZMANNR.J.1990. Splanchnic and systemic hemodynamics in mice using a radioactive microsphere technique. Am. J. Physiol., 258:G365–G369.
43.
SCHMITTMANNG., ROHRU.D.2000. Comparison of the permeability surface product (PS) of the blood capillary wall in skeletal muscle tissue of various species and in vitro porous membranes using hydrophilic drugs. J. Pharm. Sci., 89:115–127.
44.
STOTTW.T., DRYZGAM.D., RAMSEYJ.C.1983. Blood-flow distribution in the mouse. J. Appl. Toxicol., 3:310–312.
45.
TEN HOVET., VAN DEN BLINKB., PRONKI., DRILLENBURGP., PEPPELENBOSCHM.P., VAN DEVENTERS.J.H.2002. Dichotomal role of inhibition of p38 MAPK with SB 203580 in experimental colitis. Gut, 50:507–512.
46.
TIANX., ARUVAM.R., QINW.Y., ZHUW.Z., DUFFYK.T., SAUTERE.R., THAKURM.L., WICKSTROME.2004. External imaging of CCND1 cancer gene activity in experimental human breast cancer xenografts with Tc-99m-peptide-peptide nucleic acid-peptide chimeras. J. Nucl. Med., 45:2070–2082.
47.
TIANX., ARUVAM.R., QINW.Y., ZHUW.Z., SAUTERE.R., THAKURM.L., WICKSTROME.2005a. Noninvasive molecular imaging of MYC mRNA expression in human breast cancer xenografts with a [Tc-99m] peptide-peptide nucleic acid-peptide chimera. Bioconjug. Chem., 16:70–79.
48.
TIANX., ARUVAM.R., RAOP.S., QINW.Y., READP., SAUTERE.R., THAKURM.L., WICKSTROME.2003. Therapeutic oligonucleotides. Ann. N. Y. Acad. Sci., 1002:165–188.
49.
TIANX., ARUVAM.R., ZHANGK., SHANTHLYN., CARDIC.A., THAKURM.L., WICKSTROME.2007. PET imaging of CCND1 mRNA in human MCF7 estrogen receptor positive breast cancer xenografts with oncogene-specific [64Cu]Chelator-peptide nucleic acid-IGF1 analog radiohybridization probes. J. Nucl. Med., 48:1699–1707.
50.
TIANX., CHAKRABARTIA., AMIRKHANOVN.V., ARUVAM.R., ZHANGK.J., MATHEWB., CARDIC., QINW.Y., SAUTERE.R., THAKURM.L., WICKSTROME.2005b. Tumor progression and therapeutic resistance. Ann. N. Y. Acad. Sci., 1059:106–144.
51.
TSAIP.P., PACHOWSKYU., STELZERH.D., HACKBARTHH.2002. Impact of environmental enrichment in mice. 1: Effect of housing conditions on body weight, organ weights and hematology in different strains. Lab. Anim., 36:411–419.
52.
WICKSTROME., THAKURM.L., SAUTERE.R.2004. Receptor-specific targeting with complementary peptide nucleic acids conjugated to peptide analogs and radionuclides. Lett. Pept. Sci., 10:191–214.
53.
WISHL., FURTHJ., STOREYR.H.1950. Direct determinations of plasma, cell, and organ-blood volumes in normal and hypervolemic mice. Proc. Soc. Exp. Biol. Med., 74:644–648.
54.
XUL., EISEMANJ.L., EGORINM.J., D'ARGENIOD.Z.2003. Physiologically-based pharmacokinetics and molecular pharmacodynamics of 17-(allylamino)17-demethoxygeldanamycin and its active metabolite in tumor-bearing mice. J. Pharmacokinet. Pharmacodyn., 30:185–219.
55.
YUANF., LEUNIGM., BERKD.A., JAINR.K.1993. Microvascular permeability of albumin, vascular surface-area, and vascular volume measured in human adenocarcinoma Ls174t using dorsal chamber in SCID mice. Microvasc. Res., 45:269–289.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
